ALIGOS THERAPEUTICS INC ALGS
ASignal's systematic analysis rates ALGS as Bearish.
Reflects the latest available analysis · analyzed Nov 6, 2026
The case on ALGS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (2778.5% YoY)
- High financial health score (0.9)
- Low debt-to-equity ratio (0.11x)
- High cash balance ($30.38M) relative to market cap
- Current price near lower Bollinger Band (potential reversal)
- Negative MACD and slightly bearish histogram
- Price below SMA20, SMA50, and EMA20 indicating downtrend
- Negative price momentum
- Extremely negative profit and operating margins
- Negative return on equity and return on assets
- Negative free cash flow ($-61.39M)
See the full verdict on ALGS
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ALGS
Most investors never get a second opinion, let alone several. ASignal runs ALGS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.